TY - JOUR T1 - A MULTI-MINERAL INTERVENTION TO MODULATE COLONIC MUCOSAL PROTEIN PROFILE: Results from a 90-day trial in healthy human subjects JF - medRxiv DO - 10.1101/2020.12.30.20249070 SP - 2020.12.30.20249070 AU - Muhammad N. Aslam AU - Shannon D. McClintock AU - Mohamed Ali H. Jawad-Makki AU - Karsten Knuver AU - Haris M. Ahmad AU - Venkatesha Basrur AU - Ingrid L. Bergin AU - Suzanna M. Zick AU - Ananda Sen AU - D. Kim Turgeon AU - James Varani Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20249070.abstract N2 - The overall goal of this study was to determine if Aquamin®, a calcium- and magnesium-rich natural product, would alter the expression of proteins involved in growth-regulation, differentiation and barrier formation in the colon. Thirty healthy human subjects were enrolled in a three-arm, 90-day interventional trial in which Aquamin® (provided daily to deliver 800-mg of calcium per day) was compared to calcium alone and placebo. Before and after the 90-day interventional period, colonic biopsies were obtained. Biopsies were evaluated by immunohistology for expression of Ki67 (a proliferation marker) and for CK20 and p21 (differentiation markers). Tandem mass tag-mass spectrometry-based detection was used to assess levels of multiple proteins. As compared to placebo or calcium, Aquamin® reduced the level of Ki67 expression (20%). Neither intervention altered CK20 expression, while a trend toward increased p21 was observed with calcium and Aquamin® (117% and 99% respectively). In the proteomic screen, Aquamin® treatment resulted in many more proteins being upregulated or downregulated (1.5 fold-change with ≤2% false-discovery rate) than placebo. Included among the upregulated proteins were cytokeratins, cell-cell adhesion molecules and components of the basement membrane. Many of the downregulated proteins were those involved in proliferation and nucleic acid metabolism. Calcium alone also altered the expression of many of the same proteins but not to the same extent as Aquamin®. We conclude that daily Aquamin® ingestion alters protein expression profile in the colon that could be beneficial to colonic health. These data warrant additional studies with a larger sample size to validate these findings.Prevention Relevance A multi-mineral approach reduced proliferation and induced differentiation in ex vivo settings and has been shown to decrease colon polyp incidence in mouse (polyp-prevention) studies. The findings from a 90-day trial in human subjects (presented here) demonstrated improved biomarker-modulation efficacy, warranting to conduct the polyp-prevention trial in at-risk human subjects.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02647671Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT02647671 Funding StatementThis study was supported by NIH grant CA201782 including supplemental funding through the Office of Dietary Supplements (to JV) and by an MCubed (University of Michigan) grant (to MNA & ILB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical interventional trial was conducted with FDA approval of Aquamin as an Investigational New Drug (IND#118194) and with oversight by the Institutional Review Board at the University of Michigan Medical School (IRBMED)-IRB#HUM00076276. The study was registered as an interventional clinical trial with details at Clinicaltrials.gov (study identifier NCT02647671). All participants provided written informed consent prior to inclusion. This phase I trial involving human participants was carried out in accordance with recognized ethical guidelines, for example, Declaration of Helsinki, International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS), the Belmont Report and the U.S. Common Rule.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are presented either as part of the manuscript or as supplemental files. The raw mass spectrometry proteomics data is submitted on ProteomeXchange Consortium (PRIDE partner repository), the identifier is pending. ER -